The groundbreaking success of Sildenafil undeniably reshaped the pharmaceutical landscape, but investing in companies heavily reliant on generic versions presents a uncertain picture. Although early returns were impressive, the expiration of patents and the emergence of less expensive alternatives have diminished sales. Consequently, a thorough ana